Intra-Cellular Therapies (ITCI) announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, CFO. Mr. Narula will report to Dr. Sharon Mates, ITCI’s Chairman and CEO. Lawrence Hineline, who currently serves as CFO, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition. He most recently served as the CFO of Viatris (VTRS) which he joined in 2020.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
- Is ITCI a Buy, Before Earnings?
- Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
- Intra-Cellular price target raised to $100 from $94 at Needham
- Intra-Cellular downgraded to Neutral from Buy at UBS